|
EUNOIA COMPLIANCE Dr. Priyanka Murawala, PhD, DABT Biocompatibility & Toxicology Consultant |
BLOG POST ISO 10993-1:2025 Gap Assessment Service |
|
NEW STANDARD · NOVEMBER 2025 · ISO 10993-1 · BIOLOGICAL EVALUATION Is Your Device File Ready for 2025? ISO 10993-1:2025 has fundamentally changed how biological safety must be evaluated, documented, and defended. Here’s what every medical device manufacturer needs to know — and do — right now. Dr. Priyanka Murawala, PhD, DABT · Eunoia Compliance · 2025 |
|
“The era of checklist biocompatibility is closing. The era of defensible risk logic has begun.” |
INTRODUCTION
|
The sixth edition of ISO 10993-1, released in November 2025, is not a minor update. It redefines the entire framework for biological safety evaluation — shifting the industry decisively away from prescriptive test selection toward scientifically justified, risk-based reasoning embedded within lifecycle risk management. |
BACKGROUND
Why This Revision Is Structurally Different
Historically, manufacturers leaned on Table A.1 of ISO 10993-1 to identify required tests. ISO 10993-1:2025 reframes biological evaluation as a core component of risk management, directly aligned with ISO 14971. The key question is no longer “Which tests apply?” It is now: What biological hazards are reasonably foreseeable?
KEY UPDATES: 8 CHANGES
| 01. ISO 14971 Alignment | Biological evaluation is fully restructured around ISO 14971 risk management. |
| 02. Exposure Duration | New guidance on calculating exposure duration supports consistent risk assessment. |
| 03. Hazard Identification | Strengthened guidance on device characterisation is now mandatory. |
| 04. Biological Effects | “Endpoints” replaced with “effects” — focusing on clinical outcomes. |
| 05. Tissue Terminology | “Externally communicating” removed. Classified by specific tissue contact. |
| 06. Local Effects Scope | “Effects after implantation” expanded to all tissue contact devices. |
| 07. Annex A Refocused | Table A.1 replaced by 4 tissue-specific tables in the main body. |
| 08. New Annex B | New rationale for revisions added to support regulatory justification. |
IMPACT ASSESSMENT
| SITUATION | RISK | ACTION REQUIRED |
|---|---|---|
| Legacy devices (historical testing only) | HIGH | Full gap assessment + scientific justification |
| EU MDR renewal / surveillance | HIGH | BEP/BER update to 2025 structure |
| New FDA 510(k) submission | MEDIUM | Proactive gap analysis advisable |
HOW WE HELP
|
Gap Assessment with Eunoia Compliance A science-first approach tailored to your portfolio. 01 · GAP ASSESSMENT: Systematic review of BEPs, BERs, and TRAs. 02 · RISK STRATEGY: Aligned with ISO 14971 and tissue tables. 03 · TRA & E&L: Toxicological thresholds and margins of safety. 04 · READY DOCS: Defensible documentation for FDA & Notified Bodies. |
|
About the Author Dr. Priyanka Murawala, PhD, DABT Founder & CEO, Eunoia Compliance Board-certified toxicologist with 10+ years of experience. 30+ TRAs approved by FDA and EU Notified Bodies. |
|
Ready to Assess Your Gap? Don’t wait for an FDA deficiency letter. Let’s build your path to 2025 compliance. 📧 pmurawala@eunoiacompliance.com 🌐 www.eunoiacompliance.com | 📞 +1 207 266 1423 |
© 2026 Eunoia Compliance · Dr. Priyanka Murawala, PhD, DABT